PCC0208027, a novel tyrosine kinase inhibitor, inhibits tumor growth of NSCLC by targeting EGFR and HER2 aberrations

Optimizing outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when?

(2018) Nicolas Girard   Future Oncology

A Series of Enthalpically Optimized Docetaxel Analogues Exhibiting Enhanced Antitumor Activity and Water Solubility

(2018) Yun-Tao Ma et al.   JOURNAL OF NATURAL PRODUCTS

Uncommon mutations in epidermal growth factor receptor and response to first and second generation tyrosine kinase inhibitors: A case series and literature review

(2018) Giulia Galli et al.   LUNG CANCER

Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer

(2018) Shang-Gin Wu et al.   Molecular Cancer

Third generation EGFR TKIs: current data and future directions

(2018) Chee-Seng Tan et al.   Molecular Cancer

Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

(2018) Jean-Charles Soria et al.   NEW ENGLAND JOURNAL OF MEDICINE

H6, a novel hederagenin derivative, reverses multidrug resistance in vitro and in vivo

(2018) Yanting Yang et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

Nicotinic ACh receptor α7 inhibits PDGF-induced migration of vascular smooth muscle cells by activating mitochondrial deacetylase sirtuin 3

(2018) Dong-Jie Li et al.   BRITISH JOURNAL OF PHARMACOLOGY

Epidermal growth factor receptor T790M mutation: A major culprit in the progression of epidermal growth factor receptor-driven non-small cell lung cancer and the role of repeat biopsy

(2017) S Aggarwal et al.   INDIAN JOURNAL OF CANCER

Uncommon EGFR mutations in advanced non-small cell lung cancer

(2017) Grainne M. O’Kane et al.   LUNG CANCER

Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current Status of Afatinib

(2017) Bin-Chi Liao et al.   Current Oncology Reports

Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor–naïve patients with non–small cell lung cancer harboring EGFR mutations

(2017) Kentaro Tanaka et al.   Oncotarget

A peptidomimetic with a chiral switch is an inhibitor of epidermal growth factor receptor heterodimerization

(2017) Shanthi P. Kanthala et al.   Oncotarget

Epidermal growth factor receptor T790M mutation: A major culprit in the progression of epidermal growth factor receptor-driven non-small cell lung cancer and the role of repeat biopsy

(2017) S Aggarwal et al.   INDIAN JOURNAL OF CANCER

Lx2-32c, a novel semi-synthetic taxane, exerts antitumor activity against prostate cancer cells in vitro and in vivo

(2017) Guangyao Lv et al.   Acta Pharmaceutica Sinica B

The combinational therapy of trastuzumab and cetuximab inhibits tumor growth in a patient-derived tumor xenograft model of gastric cancer

(2015) C. J. Wang et al.   Clinical & Translational Oncology

Combining trastuzumab and cetuximab combats trastuzumab-resistant gastric cancer by effective inhibition of EGFR/ErbB2 heterodimerization and signaling

(2014) Lei Zheng et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Toxins from the Caribbean sea anemone Bunodeopsis globulifera increase cisplatin-induced cytotoxicity of lung adenocarcinoma cells

(2013) Heidi I Monroy-Estrada et al.   JOURNAL OF VENOMOUS ANIMALS AND TOXINS INCLUDING TROPICAL DISEASES

Afatinib—new therapy option for EGFR-mutant lung cancer

(2013) Helena A. Yu et al.   Nature Reviews Clinical Oncology

Molecular Pathology of Non–Small Cell Lung Cancer

(2012) Dara L. Aisner et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches

(2012) Antonella De Luca et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR -Mutant Lung Cancers That Lack the Second-Site EGFR T790M Mutation

(2012) Ken Takezawa et al.   Cancer Discovery

Design and Synthesis of Novel Human Epidermal Growth Factor Receptor 2 (HER2)/Epidermal Growth Factor Receptor (EGFR) Dual Inhibitors Bearing a Pyrrolo[3,2-d]pyrimidine Scaffold

(2011) Tomoyasu Ishikawa et al.   JOURNAL OF MEDICINAL CHEMISTRY